Skip to main content
. 2022 Jun 6;28(5):702–712. doi: 10.1111/hae.14595

FIGURE 5.

FIGURE 5

Median ABR in the 6 months prior to study entry and after 3 to 6 months of befovacimab treatment for participants in the low‐ (100 mg; n = 8) and intermediate‐ (225 mg; n = 8) dose cohorts. Data are shown for each participant based on their initial dose cohort. ABR, annualised bleeding rate